Clinical trial
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post-Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
NCT07388550 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post-Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 19, 2026
- Completion date
- January 1, 2028
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.